Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...

CVS Caremark, one of the nation's largest pharmacy benefit managers, will pay the Oklahoma Attorney General's Office $5 million after a settlement.

Birmingham, Alabama, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Curaechoice, the nation’s #1 leader in No-Cost Benefits Optimization Solutions, announced today that it has selected CVS Caremark at its pharmacy ...

CVS's pharmacy benefit manager, Caremark, is accused of driving independent pharmacies out of business and inflating drug costs. Federal agencies and judges have found CVS at fault for fraudulent ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

Zepbound (tirzepatide) is a brand-name injection prescribed for weight loss, weight management, and more. You may need to take Zepbound for several months to see the full effects of the drug for ...

When I walked into Zepbound’s Changing the Threads exhibit in New York City, the first thing I noticed were the clothes suspended around the space. And no, I wasn’t paying much attention to the ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...

Zepbound’s Changing the Threads exhibit in Manhattan’s uber-chic Soho area was unlike anything I’d seen before. As soon as I stepped inside, I was greeted with a flood of green lights and projections.

Intracranial electroencephalography measured the brain activity of a patient with obesity and loss-of-control eating after taking tirzepatide (Zepbound), showing the medication suppressed brain ...

GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of long Covid. Part of a class of drugs known ...

Novo Nordisk on Monday lowered the direct-to-consumer prices of its weight loss drug Wegovy and diabetes treatment Ozempic in a challenge to Eli Lilly’s Zepbound after President Donald Trump announced ...